Iovance Biotherapeutics Stock Income Statements

Iovance Biotherapeutics Quarterly Income Statements Chart

Quarterly

Annual

Operating Profit

Net Income

Iovance Biotherapeutics Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2015-12-31	2014-12-31	2014-12-31	2014-09-17	2014-06-30	2013-09-17	2013-09-17	2012-09-17	2012-09-17

revenue
product revenue	59,952,000	49,324,000	73,694,000	58,555,000	31,106,000	715,000	482,000	469,000	238,000
total revenue	59,952,000	49,324,000	73,694,000	58,555,000	31,106,000	715,000	176,750	469,000	238,000

costs and expenses
cost of sales	56,664,000	49,741,000	45,543,000	39,823,000	31,368,000	7,261,000	4,365,000	4,340,000	2,050,000
gross profit
yoy
qoq
gross margin %
research and development	79,363,000	76,879,000	72,224,000	68,245,000	62,084,000	79,783,000	87,470,000	87,526,000	86,347,000													17,586,000	17,753,000	19,653,000	16,623,000	10,837,000	8,481,000	4,463,000				5,215,074	361,227
selling, general, and administrative	37,699,000	43,925,000
total costs and expenses	173,726,000	170,545,000	160,270,000	147,621,000	133,020,000	118,437,000	121,738,000	118,830,000	110,324,000	68,534,000	58,966,000	63,627,000	70,810,000	65,110,000	51,611,000	50,165,000	39,986,000	34,943,000	35,060,000	31,378,000	26,877,000	26,071,000	22,343,000	23,581,000	20,882,000	15,922,000	18,979,000	11,727,000				55,141,399	2,110,169
income from operations	-113,774,000	-121,221,000	-86,576,000	-89,066,000	-101,914,000	-117,722,000	-121,256,000	-118,361,000	-110,086,000	-68,534,000	-58,966,000	-63,627,000	-70,810,000	-65,110,000	-51,611,000	-50,165,000	-39,986,000	-34,943,000	-35,060,000	-31,378,000	-26,877,000	-26,071,000	-22,343,000	-23,581,000	-20,882,000	-15,922,000	-18,979,000	-11,727,000				-55,141,399	-2,110,169
yoy	11.64%	2.97%	-28.60%	-24.75%	-7.42%	71.77%	105.64%	86.02%	55.47%	5.26%	14.25%	26.84%	77.09%	86.33%	47.21%	59.87%	48.77%	34.03%	56.92%	33.06%	28.71%	63.74%	17.72%	101.08%				-78.73%				-318.43%	-108.36%
qoq	-6.14%	40.02%	-2.80%	-12.61%	-13.43%	-2.91%	2.45%	7.52%	60.63%	16.23%	-7.33%	-10.14%	8.75%	26.16%	2.88%	25.46%	14.43%	-0.33%	11.73%	16.75%	3.09%	16.69%	-5.25%	12.93%	31.15%	-16.11%	61.84%					2513.13%	-106.60%	26.66%	26.66%
operating margin %
other income																																		4,103,045	4,103,045	2,813,045	2,813,045
interest and other income	4,104,000	3,220,000
net income before income taxes	-109,670,000	-118,001,000	-77,001,000	-85,061,000	-98,559,000	-114,384,000	-118,138,000	-115,003,000	-107,005,000																									31,975,292	31,975,292	25,244,352	25,244,352
income tax benefit	-1,988,000	1,838,000	-1,558,000	1,520,000	1,458,000	1,408,000	1,759,000	1,243,000	477,000
net income	-111,658,000	-116,163,000	-78,559,000	-83,541,000	-97,101,000	-112,976,000	-116,379,000	-113,760,000	-106,528,000	-68,397,000	-58,571,000	-63,018,000	-69,595,000	-63,568,000	-49,487,000	-47,551,000	-36,950,000	-32,575,000	-33,830,000	-30,660,000	-26,515,000	-25,854,000	-22,149,000	-23,377,000	-20,684,000	-15,688,000	-18,758,000	-11,563,000				-58,325,072	-2,110,169	0.00%	0.00%	0.00%	0.00%
yoy	14.99%	2.82%	-32.50%	-26.56%	-8.85%	65.18%	98.70%	80.52%	53.07%	7.60%	18.36%	32.53%	88.35%	95.14%	46.28%	55.09%	39.36%	26.00%	52.74%	31.15%	28.19%	64.80%	18.08%	102.17%				-80.17%
qoq	-3.88%	47.87%	-5.96%	-13.96%	-14.05%	-2.92%	2.30%	6.79%	55.75%	16.78%	-7.06%	-9.45%	9.48%	28.45%	4.07%	28.69%	13.43%	-3.71%	10.34%	15.63%	2.56%	16.73%	-5.25%	13.02%	31.85%	-16.37%	62.22%					2664.00%
net income margin %
net income per share	-0.33	-0.36	-0.25	-0.28	-0.34	-0.42	-0.45	-0.46	-0.47	-0.47	-0.4	-0.47																-0.23					-0.09
weighted-average shares of common stock outstanding, basic and diluted	334,511	322,868	289,877	303,269	284,817	266,220	235,131	245,817	224,481	138,301	146,492	133,162																						-31,975,292	-31,975,292	-25,244,352	-25,244,352
selling, general and administrative			27,628,500	39,553,000	39,568,000	31,393,000	29,903,000	26,964,000	21,927,000
interest income			2,674,500	4,005,000	3,355,000	3,338,000	3,118,000	3,358,000	3,081,000	137,000	395,000	609,000	1,215,000	1,542,000	2,124,000	2,614,000	3,036,000	2,368,000	1,230,000	718,000	362,000	217,000	194,000	204,000	198,000	234,000	221,000	164,000
revenues
research and development expenses										52,451,000	43,050,000	49,274,000	56,952,000	54,238,000	41,582,000	39,298,000	30,905,000	27,418,000	27,947,000	24,551,000	19,912,000
general and administrative expenses										16,083,000	15,916,000	14,353,000	13,858,000	10,872,000	10,029,000	10,867,000	9,081,000	7,525,000	7,113,000	6,827,000	6,965,000
net income per common share, basic and diluted													-550	-510	-400	-380	-300	-260	-360	-340	-310	-350	-350	-370	-330	-210	-1,150
weighted- average common shares outstanding, basic and diluted													126,568,000
weighted-average common shares outstanding, basic and diluted															124,035,000	123,567,000	123,415,000		95,077,000	90,236,000	84,350,000	65,242,000	63,332,000	62,457,000	62,286,000	55,268,000	59,113,000	51,081,519	44,410,036					-35,159,979	-35,159,979	-33,149,255	-33,149,255
general and administrative																						8,485,000	4,590,000	3,928,000	4,259,000	5,085,000	10,498,000	7,264,000
deemed dividend related to beneficial conversion feature of convertible preferred stock																											-49,454,000					-8,461,627
net income attributable to common stockholders																						-25,854,000	-22,149,000			-15,688,000	-68,212,000					-66,786,699
32.2
101.ins
101.sch
101.cal
101.def
101.lab
101.pre
november 13, 2014
operating expenses																																33,110,039	1,748,942
cost of lion transaction - related party																																16,656,250
impairment of intangible asset																																160,036
interest expense																																-2,517,945
change in fair value of derivative liabilities																																10,001,955
amortization of discount on convertible notes																																-5,497,888
cost to induce exchange transaction																																-2,295,868
financing costs																																-2,873,927
total other income																																-3,183,673
weighted-average common shares
outstanding, basic and diluted																																	24,137,782	27,712,211	27,712,211
operating expenses (including 1,227,227
40,302, and 15,835,268 of non-cash																																		160,036	160,036	160,036	160,036
share-based compensation costs)																																		-2,518,959	-2,518,959	-239,979	-239,979
private placement costs																																		10,001,955	10,001,955	-1,181,266	-1,181,266

We provide you with 20 years income statements for Iovance Biotherapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Iovance Biotherapeutics stock. Explore the full financial landscape of Iovance Biotherapeutics stock with our expertly curated income statements.

The information provided in this report about Iovance Biotherapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.